These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

65 related articles for article (PubMed ID: 8904099)

  • 1. Rufloxacin enhances susceptibility of Escherichia coli to leukocyte activity.
    Herrera I; Martinez P; Perez P; Martin M; Gomez-Lus ML; Prieto J
    J Chemother; 1995 Nov; 7 Suppl 4():36-7. PubMed ID: 8904099
    [No Abstract]   [Full Text] [Related]  

  • 2. Antimicrobial activity of a new difluorinated quinolone: lomefloxacin (SC-47111).
    Mattina R; Cocuzza G; Cocuzza CE
    J Chemother; 1989 Jul; 1(4 Suppl):159-61. PubMed ID: 16312351
    [No Abstract]   [Full Text] [Related]  

  • 3. [Effect of five fluoroquinolones on the bactericidal activity of human polymorphonuclear leukocytes against Staphylococcus aureus].
    Ballesta S; Pascual A; García I; Conejo C; Perea EJ
    Enferm Infecc Microbiol Clin; 1996 Dec; 14(10):600-3. PubMed ID: 9053002
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Microbiological studies on lomefloxacin--a new quinolone.
    Newsom SW; Rowland C
    J Chemother; 1989 Jul; 1(4 Suppl):168-9. PubMed ID: 16312354
    [No Abstract]   [Full Text] [Related]  

  • 5. Comparison of rufloxacin and norfloxacin effects on faecal flora.
    Marco F; Giménez MJ; Jiménez de Anta MT; Marcos MA; Salvá P; Aguilar L
    J Antimicrob Chemother; 1995 Jun; 35(6):895-901. PubMed ID: 7559202
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The frequency of in vitro resistance to fluoroquinolones among clinical isolates of Escherichia coli.
    Poiată A; Bădicuţ I; Grigore L; Buiuc D
    Roum Arch Microbiol Immunol; 2000; 59(1-2):63-9. PubMed ID: 11845477
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Synthesis and antibacterial activity of tricycic fluoroquinolones].
    Xiong WN; Wang EH
    Yao Xue Xue Bao; 1997 May; 32(5):347-52. PubMed ID: 11498869
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro antibacterial activity of enrofloxacin and ciprofloxacin in combination against Escherichia coli and staphylococcal clinical isolates from dogs.
    Lautzenhiser SJ; Fialkowski JP; Bjorling D; Rosin E
    Res Vet Sci; 2001 Jun; 70(3):239-41. PubMed ID: 11676620
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Suspicion of quinolone active metabolite following discrepancy between predicted and experimental urine bactericidal activities.
    Aguilar L; Giménez MJ; Costa J; Dal-Ré R; Prieto J
    Antimicrob Agents Chemother; 1997 May; 41(5):927-30. PubMed ID: 9145846
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative in-vitro activity of rufloxacin with five other antimicrobial agents against bacterial enteric pathogens.
    Soriano F; Fernández-Roblas R; López JC; García-Corbeira P; Aguilar L
    J Antimicrob Chemother; 1994 Jul; 34(1):157-60. PubMed ID: 7961202
    [No Abstract]   [Full Text] [Related]  

  • 11. Questions study on Escherichia coli susceptibility.
    Goering RV
    J Am Vet Med Assoc; 2002 Apr; 220(8):1139; author reply 1139-41. PubMed ID: 11990957
    [No Abstract]   [Full Text] [Related]  

  • 12. Vibrio parahaemolyticus chromosomal qnr homologue VPA0095: demonstration by transformation with a mutated gene of its potential to reduce quinolone susceptibility in Escherichia coli.
    Saga T; Kaku M; Onodera Y; Yamachika S; Sato K; Takase H
    Antimicrob Agents Chemother; 2005 May; 49(5):2144-5. PubMed ID: 15855551
    [No Abstract]   [Full Text] [Related]  

  • 13. Effect of the efflux pump inhibitor Phe-Arg-beta-naphthylamide on the MIC values of the quinolones, tetracycline and chloramphenicol, in Escherichia coli isolates of different origin.
    Sáenz Y; Ruiz J; Zarazaga M; Teixidó M; Torres C; Vila J
    J Antimicrob Chemother; 2004 Mar; 53(3):544-5. PubMed ID: 14762057
    [No Abstract]   [Full Text] [Related]  

  • 14. Ex vivo antibacterial properties of rufloxacin compared with those of norfloxacin in a study with healthy volunteers.
    Aguilar L; Balcabao IP; Salvá P; Martín M; Costa J; Prieto J; Dal-ré R
    Antimicrob Agents Chemother; 1996 Jan; 40(1):17-21. PubMed ID: 8787872
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Favourable effects of sub-MIC rufloxacin concentrations in decreasing the pathogen-host cell adhesion.
    Braga PC; Piatti G
    Pharmacol Res; 1993; 28(1):11-9. PubMed ID: 8234142
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Disk susceptibility testing for rufloxacin.
    Andrews JM; Wise R
    Eur J Clin Microbiol Infect Dis; 1993 Dec; 12(12):974-6. PubMed ID: 8187800
    [No Abstract]   [Full Text] [Related]  

  • 17. Effect of subinhibitory concentrations of antimicrobial agents (quinolones and macrolide) on the production of verotoxin by enterohemorrhagic Escherichia coli O157:H7.
    Yoh M; Frimpong EK; Voravuthikunchai SP; Honda T
    Can J Microbiol; 1999 Sep; 45(9):732-9. PubMed ID: 10526400
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Interaction of bactericidal serum effect and antibiotics in subminimal inhibitory concentrations on E. coli strains].
    Gillissen G; Schumacher M; Breuer-Werle M
    Pathol Biol (Paris); 1990 May; 38(5):436-40. PubMed ID: 2195453
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Accumulation of ciprofloxacin and lomefloxacinin fluoroquinolone-resistant strains of Escherichia coli.
    Xia P; Feng P; Zhong L; Lu X; Lei B
    Chin Med J (Engl); 2002 Jan; 115(1):31-5. PubMed ID: 11930654
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bactericidal activity of enoxacin and lomefloxacin against Escherichia coli KL16.
    Lewin CS; Amyes SG; Smith JT
    Eur J Clin Microbiol Infect Dis; 1989 Aug; 8(8):731-3. PubMed ID: 2506044
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.